Tislelizumab Approved as Second-Line Treatment for Advanced, Metastatic Esophageal Cancer

Sunnie Kim, MD, of University of Colorado Medicine, provides an overview of the recent FDA approval of tislelizumab for the treatment of advanced or metastatic esophageal cancer.

She shares how the therapy differs from existing second-line treatments, biomarkers or patient characteristics that may help identify individuals who are likely to respond to treatment, and further research needed to optimize the use of tislelizumab for esophageal cancer.